Regeneron Pharmaceuticals REGN has emerged as the successful bidder in the bankruptcy auction for most of the assets of ...

The bankrupt genetic-testing firm will hand over its entire data bank, including DNA samples of around 15 million people. Regeneron has said it will abide by 23andMe’s privacy policy, allowing ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

Regeneron acquires 23andMe for $256 million following its bankruptcy. The deal includes DNA data access, raising privacy ...

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

Regeneron Pharmaceuticals said in a press release yesterday that it would acquire 23andMe’s Personal Genome Service (PGS), ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

Biotechnology company Regeneron agreed to buy the assets of 23andMe, the DNA testing company that filed for bankruptcy in March, for $256 million. That’s just 4% of the San Francisco-based startup’s ...